LAS VEGAS, NV -- April 10, 2015 -- InvestorsHub NewsWire --
(PINKSHEETS:
VRCI) Verde Science, Inc., a Pharmaceutical Research and
Development Company focused on developing a portfolio of
cannabinoid based prescription medicines to meet patients needs for
a wide range of medical conditions, is pleased to announce the
addition of Shantesh Hede, Ph.D. as Director of Product
Development. Dr. Hede will be based in Mumbai, India and will
direct Verde Science’s R&D programs on-site with Verde’s
Research and Development partner, the Institute of Chemical
Technology. He earned a Ph.D. in Bioengineering Systems from
the MIT Portugal Program, a Master of Engineering Management from
Duke University, and a Bachelors in Pharmaceutical Sciences from
the Institute of Chemical Technology.
Dr. Hede stated, “Verde Science is uniquely positioned to
leverage its R&D platform alliances with existing partners in
healthcare institutions, academia and the pharmaceutical industry
for the identification and commercialization of specific
formulations derived from the marijuana plant for the treatment of
numerous medical conditions. I look forward to being a part
of this exciting effort and focusing Verde’s scientific activities
on applications that will produce significant intellectual property
in areas of limited market competition to produce substantial value
for our shareholders.”
About Verde Science, Inc. (OTCPK: VRCI)
Verde Science, Inc. (trading symbol VRCI:OTCPK) is an early stage
pharmaceutical organization that has built a research team focused
on developing a portfolio of cannabinoid prescription medicines to
meet patient needs in a wide range of medical conditions. Verde’s
scientists have identified a number of promising areas in which to
begin its immediate R&D program, which will initially be based
in India. The Verde Science team of inter-disciplinary researchers
includes scientists in Bioprocess Engineering, Nanotechnology,
Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices
that is focused on a streamlined approach to the development of
innovative treatment protocols aimed at capturing considerable
market share.
Information
For further information please see our investor profile available
on our website:
www.verdescienceinc.com
Louis Silver, Director of Investor Relations
Tel: 1-610-710-1303
lsilver@verdescienceinc.com
Safe Harbor Statements
Certain information contained in this news release constitutes
“forward-looking statements” as such term is used in applicable
United States and Canadian laws. Generally, these forward-looking
statements can be identified by the use of forward-looking
terminology such as “expects” or “does not expect”, “is expected”,
“anticipates” or “does not anticipate”, “plans”, “estimates”,
“intends” or “believes”, or that certain actions, events or results
“may”, “could”, “would”, “might” or “will be taken”, “occur”, or
“be achieved”. Forward-looking statements are based on the
opinions and estimates of management as of the date such statements
are made, and are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements. Many of
these factors are beyond the Company’s ability to control or
predict. Important factors that may cause actual results to differ
materially and that could impact the Company and the statements
contained in this news release can be found in the Company’s
filings with the SEC. Such risks and other factors include, among
others, the ability to locate and acquire suitable interests in
alternative medicine manufacturing operations on terms acceptable
to the Company, the availability of financing on acceptable terms,
accidents, labor disputes, acts of God and other risks of the
alternative medicine industry including, without limitation, delays
in obtaining governmental approvals or permits, title disputes or
claims limitations on insurance coverage. The Company believes that
the expectations reflected in the forward-looking statements
included in this news release are reasonable; however, no assurance
can be given that these expectations will prove to be correct, and
such forward-looking statements should not be unduly relied upon.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.